Tissue Sodium in Pre-hypertensive Patients

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2018-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cardiovascular disease is the first common cause of death worldwide. Hypertension is the number one driving risk factor. Hypertension has long been associated with dietary salt intake. We believe that the accumulation of salt in the interstitium and inside cells represents a neglected risk factor, which initiates a pro-inflammatory state, chronically increases blood pressure, and leads to systemic energy imbalance. We will explore the concept that Na+ storage in the skin and in muscle is associated with increased blood pressure, a pro-inflammatory state, and reduced insulin sensitivity. We will do so by addressing the following specific aims:

* Specific Aim 1: To test the hypothesis that African Americans are characterized by increased tissue Na+ storage, which is paralleled by higher blood pressure, reduced forearm blood flow, and enhanced pulse wave velocity
* Specific Aim 2: To test the hypothesis that treatment with spironolactone reduces tissue Na+ content
* Specific Aim 3: To test the hypothesis that Na+ storage leads to immune cell activation
* Specific Aim 4: To test the hypothesis that the accumulation of salt in skin and muscle is associated with decreased insulin sensitivity and propensity to diabetes mellitus

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191

Renal Insufficiency Chronic Hypertension

UNKNOWN PHASE2

Chlorthalidone in Chronic Kidney Disease

NCT02841280

Renal Insufficiency, Chronic Hypertension

COMPLETED PHASE2

Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study

NCT02299726

Acute Heart Failure

WITHDRAWN PHASE2

Skin Sodium and Salt Sensitivity of Blood Pressure

NCT05976438

Hypertension

UNKNOWN NA

Diuretic Comparison Project

NCT02185417

Hypertension

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spironolactone

50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks

Group Type ACTIVE_COMPARATOR

Spironolactone

Intervention Type DRUG

Chlorthalidone

25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks

Group Type ACTIVE_COMPARATOR

Chlorthalidone

Intervention Type DRUG

Diet

diet of 6 g salt per day for 8 weeks

Group Type ACTIVE_COMPARATOR

Diet

Intervention Type DIETARY_SUPPLEMENT

Placebo

placebo capsule administered orally 1 per day for 8 weeks

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spironolactone

Intervention Type DRUG

Chlorthalidone

Intervention Type DRUG

Diet

Intervention Type DIETARY_SUPPLEMENT

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 30 to 80 years old;
* Systolic blood pressures between 110 to 150 mmHg and/or diastolic blood pressure between 80-99 mmHg;
* Ability to give informed consent.

Exclusion Criteria

* Pregnancy;
* Intolerance to study protocols;
* Acute cardiovascular events within the previous 6 months;
* Impaired renal function \[estimated glomerular filtration rate (GFR) \< 45 ml/min/1.73m\^2\];
* Current or recent treatment with systemic glucocorticoid therapy (within 1 month of enrollment);
* Current use of anti-hypertensive medication (except calcium channel blockers and beta blockers);
* Diabetes mellitus requiring medical therapy;
* Morbid obesity (BMI \> 45);
* Prior adverse reaction to a thiazide or spironolactone;
* Claustrophobia preventing the patient from having an MRI or other contraindications to MRI;
* Impaired hepatic function (aspartate amino transaminase and/or alanine amino transaminase \> 1.5x upper limit of normal range);
* Current illicit drug use;
* Sexually active women of childbearing potential\*\* who are unwilling to practice adequate contraception during the study \[adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly\].

* Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes